Greenleaf Trust grew its holdings in Zoetis Inc (NYSE:ZTS) by 8.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,496 shares of the company’s stock after acquiring an additional 271 shares during the period. Greenleaf Trust’s holdings in Zoetis were worth $352,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ZTS. Vanguard Group Inc lifted its holdings in Zoetis by 0.8% in the third quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after acquiring an additional 293,614 shares during the last quarter. BKD Wealth Advisors LLC lifted its holdings in shares of Zoetis by 8.9% during the 4th quarter. BKD Wealth Advisors LLC now owns 2,741 shares of the company’s stock valued at $234,000 after acquiring an additional 224 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Zoetis by 2.2% during the 4th quarter. IFP Advisors Inc now owns 19,325 shares of the company’s stock valued at $1,633,000 after acquiring an additional 415 shares in the last quarter. Dowling & Yahnke LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $213,000. Finally, Calamos Advisors LLC lifted its holdings in shares of Zoetis by 15.7% during the 4th quarter. Calamos Advisors LLC now owns 57,480 shares of the company’s stock valued at $4,917,000 after acquiring an additional 7,815 shares in the last quarter. 90.95% of the stock is owned by institutional investors.

Several research firms recently weighed in on ZTS. Guggenheim began coverage on shares of Zoetis in a report on Thursday. They set a “buy” rating and a $114.00 target price on the stock. BMO Capital Markets lifted their target price on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a report on Thursday, May 9th. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Gabelli lowered shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Finally, Credit Suisse Group lifted their target price on shares of Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a report on Tuesday, April 2nd. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $103.93.

In other news, CEO Juan Ramon Alaix sold 312,109 shares of the business’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $94.06, for a total value of $29,356,972.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $101.89, for a total transaction of $203,780.00. Following the completion of the sale, the insider now directly owns 30,727 shares of the company’s stock, valued at approximately $3,130,774.03. The disclosure for this sale can be found here. Insiders have sold a total of 447,975 shares of company stock worth $42,728,902 in the last ninety days. 0.29% of the stock is currently owned by insiders.

Zoetis stock opened at $102.40 on Friday. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $104.41. The firm has a market cap of $49.01 billion, a P/E ratio of 32.72, a PEG ratio of 2.56 and a beta of 0.91. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc will post 3.48 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 19th will be paid a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 21.09%.

TRADEMARK VIOLATION WARNING: “Greenleaf Trust Acquires 271 Shares of Zoetis Inc (ZTS)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2019/05/25/greenleaf-trust-acquires-271-shares-of-zoetis-inc-zts.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Hedge Funds Explained

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.